Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of California, Davis
About this trial
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Eligibility criteria
Qualifiers
Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
Ability to provide written informed consent
Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
Negative urine pregnancy test for anyone of childbearing potential at study entry
Disqualifiers
Pregnant women
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Prisoners
Trial design
Treatments tested in this trial
- Alendronate Sodium
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
1UC Davis Comprehensive Cancer Center95817, SacramentoCalifornia, United States
Sponsors and collaborators
University of California, Davis
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Doris Duke Charitable Foundation
Collaborator
Source ClinicalTrials.gov